Drugs / Umbilical cord Wharton's jelly-derived human MSC
Umbilical cord Wharton's jelly-derived human MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04333368 | Apr 2020 → Oct 2021 | Orthocoronavirinae infectious disease, acute respiratory distress syndrome | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical cord Wharton's jelly-derived human MSC | “Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes” NCT04333368 ↗ |
| Modality | Cell therapy | “Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells” NCT04333368 ↗ |
| Route | Intravenous | “three intravenous infusions of umbilical cord Wharton's jelly-derived mesenchymal stromal cells” NCT04333368 ↗ |